Literature DB >> 25256820

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia.

Alexander Hallner1, Johan Aurelius, Fredrik Bergh Thorén, Frida Ewald Sander, Mats Brune, Kristoffer Hellstrand, Anna Martner.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25256820     DOI： 10.1111/ejh.12454

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  3 in total

1.  Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial.

Authors:  Arnaud Petit; Stéphane Ducassou; Thierry Leblanc; Marlène Pasquet; Alexandra Rousseau; Christine Ragu; Marine Cachanado; Brigitte Nelken; Yves Bertrand; Gérard Michel; Virginie Gandemer; Wendy Cuccuini; Odile Fenneteau; Hélène Lapillonne; Anne Auvrignon; André Baruchel; Guy Leverger
Journal:  Hemasphere       Date:  2018-11-29

2.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Authors:  Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

3.  Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Authors:  Roberta Kiffin; Hanna Grauers Wiktorin; Malin S Nilsson; Johan Aurelius; Ebru Aydin; Brianna Lenox; Jonas A Nilsson; Anders Ståhlberg; Fredrik B Thorén; Kristoffer Hellstrand; Anna Martner
Journal:  Front Oncol       Date:  2018-06-18       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.